The Latest Cardiac and Vascular News
In a first-of-its-kind study, Vesalius proves that its catheter-based anchoring to the papillary muscle is safe and durable VANCOUVER, BC, April 21, 2021 /PRNewswire/ — Vesalius Cardiovascular Inc. (VCI), a Canadian MedTech company developing a Transfemoral Mitral Valve Repair (TMVr) solution, announced today the achievement of a new pre-clinical milestone with its 180-day chronic animal study. The predetermined […]
MitraClip™ Guide delivery achieved in under 7.5 minutes1 TORONTO, Dec. 1, 2020 /PRNewswire/ – A recent publication demonstrated procedural efficiency for MitraClip™ transcatheter mitral valve repair (TMVR) with use of the VersaCross® RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes1. The VersaCross solution features a single radiofrequency (RF)-tipped wire used to introduce the transseptal sheath into the superior vena cava (SVC), gain transseptal access and act […]
NEWTON, Mass. and MILAN, Sept. 24, 2020 /PRNewswire/ — InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation (MR), announced today the successful First-in-Human implantation of its proprietary Saturn Transcatheter Mitral Valve along with excellent results at the 30-day follow-up for the patient, a 72 year old male suffering from severe […]
HANGZHOU, China, July 29, 2020 /PRNewswire/ — On July 23, 2020, Professor Jian’an Wang’s team at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully completed the world’s first human clinical application of the transcatheter mitral valve repair system (DragonFly™) developed by Hangzhou Valgen Medtech Co.,Ltd. This marks a major breakthrough in the field of mitral […]
New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid™ transcatheter mitral valve replacement (TMVR) system using […]
OR YEHUDA, Israel, Sept. 20, 2018 /PRNewswire/ — Cardiovalve announced today that it has commenced the AHEAD USmulticenter study (U.S. Early Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System). AHEAD US trial recruitment will start in early Q4 2018. The primary endpoint of the study is the safety and […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology company, today announced the conclusion of the PRELUDE feasibility study for its Caisson Transcatheter Mitral Valve Replacement (TMVR) system. The PRELUDE first-in-human study evaluated the Company’s TMVR system to treat moderate to severe mitral regurgitation (MR) using a transseptal approach. This is a less invasive approach […]
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety and efficacy of the treatment in patients suffering from mitral regurgitation (MR), known as a […]
CLEARWATER, Fla., July 2, 2018 /PRNewswire-USNewswire/ — On June 28, doctors at Morton Plant Hospital became the first in Florida to treat a patient in the APOLLO Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial. TMVR is a minimally invasive potential alternative to conventional open-heart mitral-valve surgery for patients with severe mitral valve regurgitation. Mitral valve regurgitation occurs when blood flows backward […]
PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of Dr. Martin T. Rothman as non-executive independent member of its Board of Directors. Dr. Rothman retired recently from his position as Vice President of medical affairs for coronary, structural […]
